Revvity opens the weekend with strategy focus, shares on NYSE radar
Published on 06/27/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-27, 12:32.
Revvity Inc. (US76155R1086) stands out this weekend with its long-term life-sciences and diagnostics strategy in focus. The former PerkinElmer stock trades on the NYSE and competes with sector peers such as Danaher and Thermo Fisher Scientific in high-value laboratory technologies.
What current sources show
Revvity, rebranded from PerkinElmer in 2023, positions itself as a global provider of instruments, reagents and software for drug discovery and clinical diagnostics, targeting recurring revenues from consumables and services. The company’s shares, listed under the ticker RVTY on the NYSE, align with large-cap US life-sciences tools players but remain outside the S&P 500 index.
Analyst coverage compiled by third-party platforms indicates a generally constructive view on the life-sciences tools sector, with large peers such as Danaher and Thermo Fisher widely rated Buy by major houses including Goldman Sachs and JPMorgan. This sector backdrop frames expectations for Revvity’s growth prospects and margin resilience in diagnostics and applied markets.
Long-term strategy and positioning
According to company descriptions aggregated by Bitget and other data providers, Revvity’s strategy centers on providing integrated solutions across instruments, consumables and software for pharmaceutical R&D, clinical testing and environmental analysis. This mix seeks to balance cyclical capital-expenditure demand with steadier consumables and services revenue streams.
The rebranding from PerkinElmer to Revvity marked a strategic emphasis on precision medicine and advanced diagnostics, positioning the group alongside global peers such as Danaher’s Cytiva unit and Thermo Fisher’s clinical diagnostics franchises. Sector commentary from major research houses on life-sciences tools highlights structural drivers like rising biopharma R&D spend and growing demand for high-throughput, automated testing platforms.
Background and price data on Revvity
Further figures, news and historical performance data on the Revvity shares are available in the dedicated topic section and via the company’s investor-relations page.
The product behind the stock
Revvity’s business centers on laboratory instruments, reagents and software used in areas such as genomics, imaging and clinical diagnostics. Representative solutions include high-throughput screening platforms and diagnostic assays that support pharmaceutical companies and clinical laboratories in drug discovery and patient testing workflows.
Where the stock trades today
The Revvity shares (US76155R1086) trade on the NYSE under the ticker RVTY; the latest price and market capitalization figures are published by the exchange and major data providers and reflect US dollar trading.
Key data on the Revvity shares
- Company: Revvity Inc.
- ISIN: US76155R1086
- WKN: not available
- Ticker: RVTY
- Trading venue: NYSE
- Price (as of 2026-06-27, 10:30): not live-verifiable USD
- Market cap: not live-verifiable USD (as of 2026-06-27)
- Sector / industry: Life sciences tools and diagnostics
- Index membership: not documented in major benchmark indices
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation or an offer to buy or sell any securities. Data and assessments are based on sources believed to be reliable but cannot be guaranteed for accuracy or completeness.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
